Alembic Pharmaceuticals Limited (APLLTD)
Please find attached Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.
Press Release - Q1FY27
- Revenue from operations increased 26% y-y to Rs 2150 Cr; PAT up 12% to Rs 173 Cr
- India Branded Business grew 7% to Rs 642 Cr; strong growth in Gynaecology, Gastrology, Ophthalmology
- US Formulation revenue surged 49% to Rs 778 Cr with 7 new launches
- Ex-US Generics up 17% to Rs 383 Cr; 10 ANDA approvals received
- API business grew 33% to Rs 346 Cr
- MD: "Strong start to FY27 with broad-based growth and focus on pipeline advancement"
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 APLLTD — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add APLLTD to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alembic Pharmaceuticals Limited
Important.
The summary above is generated automatically from Alembic Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.